Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: Final results of the Japan Clinical Oncology Group Study, JCOG 9809

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1382-1391

  Ohmachi, K ^a   Tobinai, K ^b   Kobayashi, Y ^b   Itoh, K ^c   Nakata, M ^c   Shibata, T ^d   Morishima, Y ^e   Ogura, M ^e   Suzuki, T ^f   Ueda, R ^g   Aikawa, K ^h   Nakamura, S ^e   Fukuda, H ^d   Shimoyama, M ⁱ   Hotta, T ^a,i  

^a TOKAI UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f SHIGA MEDICAL CENTER FOR ADULTS   (Japan)

^g NAGOYA CITY UNIVERSITY   (Japan)

^h HOKKAIDO CANCER CENTER   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Aggressive non Hodgkin's lymphoma; CHOP 14; CHOP 21; Phase III trial

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER STAGING; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EWING SARCOMA; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMACH PERFORATION; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; UTERINE CERVIX CANCER; WALLENBERG SYNDROME;

EID: 79957797972     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq619     Document Type: Article

References (30)

1. cKelvey EM, Gottlieb JA, Wilson HE. et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
2. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-1030.
3. Gordon LI, Harrington D, Andersen J. et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349.
4. Cooper IA, Wolf MM, Robertson TI. et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 1994; 12: 769-778.
5. Montserrat E, Garcia-Conde J, Vinolas N. et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol 1996; 57: 377-383.
6. Fisher RI, Gaynor ER, Dahlberg S. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
7. Kwak LW, Halpern J, Olshen RA. et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977.
8. Haioun C, Lepage E, Gisselbrecht C. et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-1137.
9. Gianni AM, Bregni M, Siena S. et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
10. Itoh K, Ohtsu T, Fukuda H. et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated GCSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002; 13: 1347-1355.
11. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-2135.
12. Lister TA, Crowther D, Sutcliffe SB. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
14. Tobinai K, Kohno A, Shimada Y. et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-257.
15. Kim K, DeMets DL. Confidence intervals following group sequential tests in clinical trials. Biometrics 1987; 3: 857-864.
16. Spiegelhalter DJ, Freedman LS, Parmar MK. Applying Bayesian ideas in drug development and clinical trials. Stat Med 1993; 12: 1501-1511.
17. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001.
18. Pfreundschuh M, Trümper L, Kloess M. et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
19. Pfreundschuh M, Trümper L, Kloess M. et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
20. Pfreundschuh M, Loeffler M. Author response: a different view of "standards" in the treatment of aggressive lymphomas. Blood 2004; 104: 1585-1586.
21. Coiffier B, Salles G. Letter to the editor: immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. Blood 2004; 104: 1584-1585.
22. Wunderlich A, Kloess M, Reiser M. et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003; 14: 881-893.
23. Verdonck LF, Notenboom A, de Jong DD. et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007; 109: 2759-2766.
24. Hudson MM, Mulrooney DA, Bowers DC. et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol 2009; 27: 2405-2414.
25. Lyman GH, Dale DC, Wolff DA. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28: 2914-2924.
26. Bhatia S, Robinson LL, Francisco L. et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215-4222.
27. Relling MV, Boyett JM, Blanco JG. et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101: 3862-3867.
28. Coiffier B, Lepage E, Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
29. Pfreundschuh M, Trumper L, Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
30. Delarue R, Tilly H, Salles G. et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009; 114: 169 (Abstr 406).